| Literature DB >> 35647522 |
Fernando M Ruggiero1, Sebastian Springer1.
Abstract
Through the presentation of peptide antigens to cytotoxic T lymphocytes, major histocompatibility complex (MHC) class I molecules mediate the adaptive immune response against tumors and viruses. Additional non-immunological functions include the heterotypic association of class I molecules with cell surface receptors, regulating their activities by unknown mechanisms. Also, homotypic associations resulting in class I dimers and oligomers - of unknown function - have been related to pathological outcomes. In this review, we provide an overview of the current knowledge about the occurrence, biochemical nature, and dynamics of homotypic and heterotypic associations of class I molecules at the cell surface with special focus on the molecular species that take part in the complexes and on the evidence that supports novel biological roles for class I molecules. We show that both heterotypic and homotypic class I associations reported in the literature describe not one but several kinds of oligomers with distinctive stoichiometry and biochemical properties.Entities:
Keywords: Closed conformers; Dimers; Empty conformers; Free heavy chain; Heterotypic associations; Homotypic associations; MHC class I; Non-covalent associations; Oligomers; Open conformers
Year: 2022 PMID: 35647522 PMCID: PMC9133507 DOI: 10.1016/j.crimmu.2022.05.001
Source DB: PubMed Journal: Curr Res Immunol ISSN: 2590-2555
Fig. 1Known species of MHC class I monomers and dimers. Schematic representation of the different molecular species of class I molecules (HβP, Hβ and H) found at the cell surface. P: antigenic peptide; H: class I transmembrane heavy chain; β: beta-2 microglobulin. Non-covalent homotypic associations between class I species (HβP/HβP, HβP/H and H/H) of the same or different allotypes (Table 1). Covalently bound class I dimers. For those dimers formed between free heavy chains (H), the same or different allotypes might be involved, and the disulfide bond links the extracellular domains (H-H) or the cytosolic domains (H.H). Covalent dimers of HβP species (HβP-HβP) were only reported for HLA-G (Table 1). Example of heterotypic association. The non-covalent interaction between HβP or H with the insulin receptor (IR) is depicted as an example. The structure of the IR is simplified and does not reflect the actual structure of the receptor. Different interacting partners were described in the literature (Table 2). For clarity, only dimeric associations of a single allotype are shown.
Some reported homotypic in cis interactions between class I molecules.
| Allotype | Species in the complex | Homotypic association | Cells, mice, model | Antibody | Methodology | Ref. |
|---|---|---|---|---|---|---|
| HLA-A2, B7, C7 | H | Oligomers | JY cells | HC-10 | FRET by flow cytometry | |
| HLA-A2, B7, C7 | HβP | JY cells | KE-2 | EEQ by flow cytometry | ||
| HLA-A, B, C | HβP | Activated B or T-cells | KE-2 | EEQ by flow cytometry | ||
| HLA-A2 | HβP | Between HLA-A2 | JY cells | BB7.2 | FRET by flow cytometry | |
| HLA-A2 | HβP | Affinity purified (BB7.2) and labelled HLA-A2 reconstituted in liposomes | – | FRET by flow cytometry, TPA, FRAP | ||
| H | Dimers | HCT-Ld3 cells | 28.14.8, 64.3.7 | Cell surface labeling using125I or metabolic labeling followed by IP | ||
| H-2Db, H-2Ld | H | Dimers | Eld3 cells | 28.14.8 | ||
| H-2d | HβP, Hβ | H-2Ld dimers | BALB/c splenocytes | 28.14.8 | ||
| H-2Ld | H | H-2Ld dimers | BALB/c splenocytes | 64.3.7 | ||
| H-2b | HβP, Hβ | H-2Db dimers | C57BL/6 splenocytes | 28.14.8 | ||
| H-2Dd | H, Hβ | Dimers | 18.48 cells | 34.2.12 | ||
| H | Non-covalent dimers | STF1 cells transfected with H-2Kb | – | Two-hybrid assay based on antibody micropatterns | ||
| HβP | Between Kb bound to OVA peptide SIINFEKL | L-Kb cells | 25-D1.16 | TIRFM | ||
| HβP | Non-covalent dimers mediated by N-linked sugars | Extracellular domain of H-2Kb fused to His tag and captured by Nickel-chelating lipid in artificial bilayers | – | Two-dimensional crystallization followed by electron microscopy and molecular replacement calculations | ||
| HLA-A2, B7, C7, | HβP and H | Dimers and trimers | Raji cells | W6/32 | Cell surface biotinylation or metabolic labeling followed by IP | |
| HLA-A2, B7, C7 | HβP | Dimers and trimers | JY cells | W6/32, | SNOM, FRET by flow cytometry, pbFRET | |
| H-2Kb | HβP | Oligomers | EL4 cells | AF6-88.5 | TEM | |
| H-2Db | HβP | Oligomers | Dendritic cells | B22.249 | ||
| HLA-A9, A25, B7, B41 | HβP | Oligomers | Jurkat cells | W6/32 | ||
| HβP, Hβ | Between HLA-A2-YFP with itself or with endogenously expressed A2, B7 or C7 | JY cells | – | TIRFM | ||
| HLA-A2, B7, C7 | HβP | Each allotype with itself or with any other allotype | JY cells | W6/32 | AFM, TEM, FRET by flow cytometry | |
| HLA-A66 | HβP | Between HβP of HLA-A66 | HUT-102B2 cells | W6/32 | ||
| HLA-A2, B7, C7 | HβP | Each allotype with itself or with any other allotype | JY cells | W6/32, | FRET by flow cytometry, pbFRET | |
| HLA-B27 | H | Dimers | – | HC-10 | In vitro refolding followed by R SDS-PAGE and SEC | |
| HLA-B27 | H | Tetramers | T2 cells transfected with HLA-B27 | W6/32 (IP) | Cell surface biotinylation followed by IP and NR SDS-PAGE | |
| HLA-A2, B7, C7 | HβP, Hβ | Each allotype with itself or with any other allotype | JY cells | – | Cross-linked MS | |
| HLA-A2, B27, C1 | H | Dimers | Jesthom cells | HC-10 | NR SDS-PAGE | |
| HLA-A2, B27, C1 | H | Dimers | Jesthom exosomes | HC-10 | NR/R SDS-PAGE, | |
| HLA-A2 | H | Dimers of HLA-A2 | Jesthom exosomes | HCA2 | NR 2D electrophoresis | |
| HLA-A2, B27, C1 | H | Dimers | Jesthom exosomes | HC-10, HCA2 | NR 2D electrophoresis | |
| HLA-A2, B27, C1 | HβP, H | HβP/H Dimers | Jesthom exosomes | W6/32 (IP), HC-10 (blot) | IP followed by NR SDS-PAGE | |
| HLA-A2, B27, C1 | HβP, H | Dimers of HLA-B27 HβP with H of itself or H of any other allotype | Jesthom exosomes | ME1 (IP), | IP followed by NR SDS-PAGE | |
| HLA-A2 | HβP, H | HβP/H dimers of HLA-A2 | Jesthom exosomes | BB7.2 (IP), HCA2 (blot) | IP followed by NR SDS-PAGE | |
| HLA-A2, B27, C1 | HβP, H | Dimers between HβP of HLA-A2 and H of any other allotype | Jesthom exosomes | BB7.2 (IP), | IP followed by NR SDS-PAGE | |
| H | Dimers of HLA-B27 | Exosomes of C58 cells transfected with HLA-B27 | HC-10 | NR SDS-PAGE | ||
| H | Dimers | Exosomes of C58 cells transfected with wild-type or cytoplasmic domain-deleted “tail-less” HLA-A2 | HCA2 | NR SDS-PAGE | ||
| HLA-A30, A31, | H | Dimers detected in B27 transfected cells. In non-transfected cells, dimers are undetectable | Exosomes of KG-1 cells transfected with HLA-B27 | HC-10 | NR SDS-PAGE | |
| HLA-A30, A31, | H | Dimers | KG-1 cells | HCA2 | NR SDS-PAGE | |
| H | Dimers | Exosomes of LCL 721.221 cells transfected with wild-type, C308A or C325A HLA-B27 | HC-10 | NR SDS-PAGE | ||
| HLA-A2, B27, C1 | H | Dimers of endogenously expressed allotypes only detectable after diamide treatment | Jesthom cells | HC-10 | NR SDS-PAGE | |
| HLA-A2, B27, C1 | HβP | Dimers of endogenously expressed allotypes only detectable after diamide treatment | Jesthom cells | W6/32 | IP followed by NR SDS-PAGE | |
| HLA-A1, A31, | H | Dimers | CEM cells transfected with HLA-B27 | HC-10 | NR SDS-PAGE | |
| H | Dimers | Exosomes of LCL 721.221 cells transfected with wild-type, C308A or C325A HLA-B27 | HC-10 | |||
| H | Dimers | Exosomes of C58 cells transfected with wild-type or cytoplasmic domain-deleted “tail-less” HLA-A2 | HCA2 | |||
| H | Dimers | LCL 721.221 cells transfected with HLA-B7 | HC-10 | NR/R SDS-PAGE, mutagenesis | ||
| H | Dimers of HLA-B27 | LCL 721.221 cells transfected with HLA-B27 | HC-10 | NR SDS-PAGE | ||
| H | Dimers of HLA-A2 | LCL 721.221 cells transfected with HLA-A2 | HCA2 | NR SDS-PAGE | ||
| H | Dimers of HLA-A3 | LCL 721.221 cells transfected with HLA-A3 | HCA2 | NR SDS-PAGE | ||
| HβP | Dimers | LCL 721.221 cells transfected with HLA-G | BBM.1 | Cell surface biotinylation followed by IP and NR/R SDS-PAGE | ||
| HβP | Dimers | LCL 721.221 cells transfected with HLA- A2 | BBM.1 | |||
| HβP | Dimers | LCL 721.221 cells transfected with HLA-G | MEM-G/09 (IP) | Cell surface biotinylation followed by IP and 2D (NR/R) SDS-PAGE | ||
| HLA-G | HβP | Dimers | Jeg-3 cells | MEM-G/09 (IP) | Cell surface biotinylation followed by IP and 2D (NR/R) SDS-PAGE | |
| HLA-G | HβP | Dimers through Cys-42 | – | – | In vitro refolding followed by crystallization | |
| HLA-G | HβP | Dimers | Human-derived first-trimester trophoblast cells | MEM-G/11 (IP), 87G (IP) | Cell surface biotinylation followed by IP and NR/R SDS-PAGE | |
| HLA-G | HβP | Dimers | G233 (IP) | |||
Abbreviations: AFM: atomic force microscopy; APCs: antigen presenting cells; CTL: cytotoxic T lymphocytes; EEQ: electron-exchange quenching; FRAP: fluorescence recovery after photobleaching; FRET: Förster resonance energy transfer; pFRET: photobleaching FRET; IP: immunoprecipitation; MS: mass spectrometry; NR SDS-PAGE: non-reducing SDS-polyacrylamide gel electrophoresis; R SDS-PAGE: reducing SDS-PAGE; SEC: size exclusion chromatography; SNOM: scanning near field optical microscopy; TEM: transmission electron microscopy; TIRFM: total internal reflection fluorescence microscopy; TPA: time-resolved phosphorescence anisotropy.
Notes: First column shows endogenously expressed (not bold) and transfected (bold) allotypes by each cell line. A list of the allotypes expressed by cells and mice, the binding specificity, and the class I species (HβP, Hβ or H) that are recognized by antibodies can be found in Table 3, Table 4, respectively.
HβP associations that were only detected when HC-10 reactive class I molecules (H) were also present, or HβP associations that were reduced after addition of exogenous β2m.
Uncertainty about the class I molecular species (HβP, Hβ and/or H) involved in the homotypic association.
Each allotype with itself or with other allotypes. Not possible to unequivocally define which of the allotypes took part in the described association.
Dimers sensitive to reducing agents.
Covalent dimers confirmed by mutagenesis.
Some heterotypic in cis interactions of class I molecules from the literature.
| Allotype | Species in the complex | Associated | Cells, mice, model | Antibody | Methodology | Ref. |
|---|---|---|---|---|---|---|
| H-2Db, H-2Kb | HβP | Insulin receptor | C57BL/6J mice | 20.8.4 | Cell surface labeling of IR with125I-photoreactive insulin analog followed by IP and SDS-PAGE | |
| H-2Kk, H-2Dk | HβP | AKR/J mice | 3.83 | |||
| H-2Kk | HβP | Insulin receptor | C3H mice | H-100-30/23, 3.83, | Cell surface labeling of IR with125I-photoreactive insulin analog followed by IP and SDS-PAGE | |
| H-2Dk | HβP | C3H mice | H-100-30/23, 3.83 | |||
| H-2Kb, H-2Db | HβP | C57BL/6J mice | 20.8.4 | |||
| HβP, Hβ | Insulin receptor | RE1 cells transfected with β2m and H-2Db | 28.14.8 | Cell surface labeling of IR with125I-photoreactive insulin analog followed by IP and SDS-PAGE | ||
| H-2Kk | HβP | Insulin receptor | C3H mice | 11.4.1 | Cell surface labeling of IR with125I-photoreactive insulin analog followed by IP and SDS-PAGE | |
| H-2Dk | C3H mice | 15.5.5S | ||||
| H-2Ks | HβP | B10.S mice | 34.1.2 | |||
| H-2Kb | HβP | BALB/B mice | 28.13.3 | |||
| H-2Db | HβP, Hβ | BALB/B mice | 28.14.8 | |||
| H-2Ks | HβP | Insulin receptor | NIH 3T3 HIR cells | R1-9.6 | FRET by flow cytometry | |
| H-2Ks | CP28 | |||||
| H-2Dq, H-2Lq | HβP | 30.5.7 | ||||
| H-2Dq, H-2Lq | HβP, Hβ, H | 28.14.8 | ||||
| H-2b | Insulin receptor | C57BL/6J mice | anti IRβ (IP) MCA51R (blot) | IP followed by SDS-PAGE | ||
| HLA-A3 | HβP, H | Insulin receptor | U937 cells | 4F2 (IP), | Cell surface labeling of IR with125I-photoreactive insulin analog followed by IP and SDS-PAGE | |
| HLA-A1 | Insulin receptor | LCL 721.13 cells | GSC142.1 | Cell surface labeling of IR with125I-insulin, followed by cross-linking, IP, and SDS-PAGE | ||
| HLA-A2 | HβP | LCL 721.1 cells | BB7.2 | |||
| HLA-A2 | HβP | LCL 721.45.1 cells | BB7.2 | |||
| HLA-A2 | HβP | LCL 721.53 cells | BB7.2 | |||
| HLA-A2 | HβP | LCL 721.1 cells | PA2.1 | |||
| HβP | 961 cells | anti β2m | ||||
| HLA-B8 | LCL 721.13 cells | B8 | ||||
| HLA-A2, A25 | HβP, H | Insulin receptor | IM-9 cells | B8.1.23.2 | Cell surface labeling of IR with125I- insulin analog followed by crosslinking, IP and SDS-PAGE | |
| B21, B22, Cw4 | HβP | |||||
| HLA-A2 | H | Insulin receptor | Proteoliposomes | – | FRET by flow cytometry using proteoliposomes containing purified IR and HLA-A2 | |
| H-2Kk, H-2Dk | HβP | LH/hCG receptors | Ovaries of C3H mice | 3.83 or 16.1.2 | Homogenates incubated with125I-hCG followed by IP with anti-MHC mAbs and reprecipitation of LH/hCG receptors by polyethylene glycol | ( |
| H-2Kd | HβP | Ovaries of BALB/c mice | 34.1.2 | |||
| H-2Dd | H | 34.2.12 | ||||
| HLA-A, B, C | HβP | CD1a | Human thymic-derived cells | W6/32 | Cell surface iodination (125I) followed by IP, SDS-PAGE and chymotryptic peptide mapping | |
| HLA-A, B, C | HβP, H | A1.4 | ||||
| HLA-A, B, C | HβP | CD8 | Human activated PBTC | anti-CD8 | Cell surface iodination (125I) followed by IP, SDS-PAGE and chymotryptic peptide mapping | |
| HLA-A, B, C | HβP | W6/32 | ||||
| HLA-A, B, C | HβP | CD8 | T cell clone, activated T cells | W6/32, BB7.7 | Metabolically labelling of cells followed by cell surface cross-linking, IP, SDS-PAGE and chymotryptic peptide mapping | |
| HLA-A, B, C | H | CD8 | Activated PBL | HC-10 | Cell surface biotinylation followed by IP and SDS-PAGE | |
| H-2Kk | HβP | CD8 | KB5.C20 cells | Anti-CD8 | Cell surface iodination (125I) followed by IP and SDS-PAGE | |
| H-2Kk | HβP | H-100-5/28 | ||||
| HLA-A66 | HβP | IL-2 receptor | HUT-102B2 cells | W6/32 | Metabolically labelling of cells followed by, IP, SDS-PAGE and proteolytic peptide mapping | |
| HLA-A66 | HβP | IL-2 receptor | HUT-102B2 cells | W6/32 | FRET by flow cytometry | |
| HLA-A, B, C | HβP | IL-2 receptor | Activated PBTC | W6/32 | FRET by flow cytometry | |
| HLA-A, B, C | HβP | IL-2 receptor | FT7.10 cells | W6/32 | FRET by flow cytometry, apFRET | |
| HLA-A66 | HβP | IL-2 receptor | HUT-102B2 cells | KE-2 | FRAP | |
| HLA-A, B, C | HβP | IL-15 receptor | FT7.10 cells | W6/32 | FRET by flow cytometry, apFRET | |
| H | Ly49A | C1498 cells transfect- ed to express H-2Dd | 34.2.12 | IP followed by SDS-PAGE | ||
| H-2Db | H141-30 | |||||
| Ly49A | C1498 cells transfect-ed to express HA-H 2Dd and VSV-Ly49A | anti-VSV (IP) | Cell surface cross-linking followed by IP and SDS-PAGE | |||
| HLA-A3, B07, C07 | HβP | HLA-DR | PGF cells | W6/32 | FRET by flow cytometry | |
| HβP | HLA-DQw1,3 | W6/32 | ||||
| HβP | HLA-DQw1 | W6/32 | ||||
| HβP | HLA-DP | W6/32 | ||||
| HLA-B7 | HβP | HLA-DR | BB7.1 | |||
| HLA-B7 | HβP | HLA-DQw1,3 | BB7.1 | |||
| HLA-B7 | HβP | HLA-DP | BB7.1 | |||
| HLA-A3 | HβP | HLA-DR | GAP-A3 | |||
| HLA-A3 | HβP | HLA-DQw1,3 | GAP-A3 | |||
| HLA-A3 | HβP | HLA-DP | GAP-A3 | |||
| HLA-A3, B07, C07 | HβP | HLA-DR | JY cells | W6/32 | FRET, TEM, AFM | |
| HLA-A66 | HβP | HUT-102B2 cells | W6/32 | |||
| HLA-A2 | HLA-DQA | JY cells | – | Cross-linked MS | ||
| HLA-A2 | HLA-DRA | – | ||||
| HLA-A2 | HLA-DRB | – | ||||
| HLA-B7 | HLA-DRA | – | ||||
| HLA-B7 | HLA-DRB | – | ||||
| HLA-C7 | HLA-DRA | – | ||||
| HLA-C7 | HLA-DRB | – | ||||
| HLA-A3 | H | HLA-F | PLH cells | anti HLA-F (IP), HCA2 (blot) | IP followed by SDS-PAGE | |
| HLA-A66 | HβP | ICAM-1 | HUT-102B2 cells | W6/32 | Cell surface iodination (125I) followed by IP and SDS-PAGE | |
| HLA-A2 | ICAM-1 | JY cells | PA2.1 | Cell surface biotinylation followed by cross-linking, IP and SDS-PAGE | ||
Abbreviations: AFM: atomic force microscopy; FRAP: fluorescence recovery after photobleaching; hCG: human chorionic gonadotrophin; MS: mass spectrometry; IP: immunoprecipitation; IR: insulin receptor; LH: luteinizing hormone; mAb: monoclonal antibody; PBTC: peripheral blood T cells; PBL: peripheral blood lymphocytes; apFRET: acceptor photobleaching FRET.; TEM: transmission electron microscopy.
Notes: First column shows endogenously expressed (not bold) and transfected (bold) allotypes by each cell line. A list of the allotypes expressed by cells and mice, the binding specificity, and the class I species (HβP, Hβ or H) that are recognized by antibodies can be found in Table 3, Table 4, respectively.
Associations were reduced after addition of exogenous β2m.
Uncertainty about the molecular species (HβP, Hβ and/or H) involved in the heterotypic association.
Chemical cross-linking of the cell surface is necessary to detect or enhance detection of interacting proteins.
Human and mouse class I allotypes expressed by cell lines and mice.
| Cell line/mouse strain | Expressed allotypes | Ref. |
|---|---|---|
| 961 | HLA-B5. Generated by stable HLA-B5 expression in the HLA negative LCL 721.221 cell line | ( |
| 18.48 | H-2Ld | |
| C1498 | NK T cell line derived from H-2b mice | ( |
| C58 | Rat-derived cell line | |
| CEM | HLA-A1, A31, B8, B40 | |
| EL4 | H-2b | ( |
| ELd3 | H-2b, H-2Ld (an H-2Ld transfectant of EL4 cells) | ( |
| FT7.10 | HLA-A, B, C | |
| HCT-Ld3 | HLA negative, β2m negative, human cell line. Stably transfected to express H-2Ld | ( |
| HUT-102B2 | HLA-A66 | |
| IM-9 | HLA-A2, A25, B21, B22, Cw4 | |
| Jeg-3 | HLA-G | |
| Jesthom | HLA-A2, B27, C1 | |
| Jurkat | HLA-A9, A25, B7, B41 | |
| JY | HLA-A2, B7, C7 | |
| KB5.C20 | H-2k | |
| KG-1 | HLA-A30, A31, A33, B35 | ( |
| LCL 721.1 | HLA-A2, B5, C | ( |
| LCL 721.13 | HLA-A1, B8, C | ( |
| LCL 721.221 | HLA negative | |
| LCL 721.45.1 | HLA-A2, B5, C | ( |
| LCL 721.53 | HLA-A2, C | ( |
| L-Kb | L929 mouse fibroblasts (H-2k) stably transfected to express H-2Kb | ( |
| NIH 3T3 HIR | NIH 3T3 (H-2Dq, H-2Ks, H-2Lq) stably transfected to express the human IR | |
| PGF | HLA-A3, B7, C7 | |
| PLH | HLA-A3, B47, C6 | |
| Raji | HLA-A3, B15, C3, C4 | |
| RE1 | β2m negative, H-2 negative | ( |
| STF1 | HLA-A3, B15, C14 | ( |
| T2 | HLA-A2, B5 | |
| U937 | HLA-A3, A31, B18, B51, C1, C7 | |
| AKR/J mice | H-2k | |
| B10.S mice | H-2s | |
| BALB/B mice | H-2b | |
| BALB/c mice | H-2d | |
| C3H mice | H-2k | |
| C57BL/6 mice | H-2b | ( |
IR: insulin receptor.
Allotype and species (HβP, Hβ, H) specificities of antibodies to human and mouse class I molecules.
| Antibody | Allotype | Recognized species | Ref. |
|---|---|---|---|
| 11.4.1 | H-2Kk | HβP | ( |
| 15.5.5S | H-2Dk. Cross-reaction with H-2Kd, H-2Kf | 2 | |
| 16.1.2 | H-2Kk. Cross-reactions with H-2Kq, H-2Kp, H-2Kr | HβP | ( |
| 16.3.1 | H-2Kk. Cross-reactions with H-2Kq, H-2Kp, Kr | HβP | ( |
| 20.8.4 | H-2Db, H-2 Kb | HβP | ( |
| 25-D1.16 | SIINFEKL-pulsed H-2Kbcells | HβP | ( |
| 28.13.3 | H-2Kb | HβP | |
| 28.14.8 | H-2Ld, H-2Lq, H-2Db, H-2Dq | HβP, Hβ and H | ( |
| 3.83 | H-2Dk, H-2Kk. Cross-reaction with H-2Kb, H-2Ks, H-2Kq, H-2Kp, H-2Kr | HβP | |
| 30.5.7 | H-2Ld, H-2Dq. Cross-reactions with H-2Lq | HβP | ( |
| 34.1.2 | H-2Kd. Cross-reaction with H-2Kb, H-2Ks, H-2Kq, H-2Kp, H-2Kr | HβP | ( |
| 34.2.12 | H-2Dd | H | ( |
| 34.4.20 | H-2Kb | HβP | |
| 4F2 | α chain of the IR | – | ( |
| 64.3.7 | H-2Ld, H-2Lq, H-2Kd | H | ( |
| 87G | HLA-G1 | HβP | |
| A1.4 | HLA-A, B, C | HβP and H | ( |
| AF6-88.5 | H-2Kb | HβP | |
| B22.249 | H-2Db | HβP | ( |
| B8 | HLA-B8 | ||
| B8.1.23.2 | HLA-A, B, C | HβP and H | |
| B9.12.1 | HLA-A, B, C | HβP | |
| BB7.1 | HLA-B7 | HβP | |
| BB7.2 | HLA-A2, A28 | HβP | ( |
| BB7.7 | HLA-A, B, C | HβP | |
| BBM.1 | β2m (free β2m and non-covalently linked β2m to HLA molecules) | HβP | |
| CP28 | H-2Dd, Ds. Cross-reaction with Ks | HβP? | ( |
| G233 | HLA-G | HβP | |
| GAP-A3 | HLA-A3 | HβP | |
| GSC142.1 | HLA-A1 | ||
| H-100-30/23 | H-2Dk, H-2Kk | HβP? | ( |
| H-100-5/28 | H-2Kk | HβP | ( |
| H141-30 | H-2Db | ||
| HC-10 | HLA-B. Cross-reaction with HLA-C and HLA-A | H | ( |
| HCA2 | HLA-A | H | ( |
| KE-2 | HLA-A, B, C | HβP | |
| MCA51R | H-2b | HβP | ( |
| ME1 | HLA-B7, B27, B22 | HβP | ( |
| MEM-G/09 | HLA-G1 | HβP | |
| MEM-G/11 | HLA-G | HβP | |
| PA2.1 | HLA-A2 | ( | |
| PA2.6 | HLA-A, B, C | HβP | |
| R1-9.6 | H-2Kb, H-2Kk, H-2Ks, H-2Db, H-2Dd, H-2Df, H-2Ld | HβP | ( |
| W6/32 | HLA-A, B, C | HβP | ( |
IR: insulin receptor.
Uncertainty about the molecular species (HβP, Hβ and/or H) recognized by the antibody.
A specific variant of HLA-A*28 is recognized by BB7.2.